Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Dedicated

- PMLiVE

Prostate cancer treatment market to treble to £8.2bn by 2023

But GlobalData predict growth could be hampered by patent loss for Zytiga

- PMLiVE

Eylea growth closes the gap with Lucentis

Bayer/Regeneron’s drug eye disease drug set for blockbuster status

- PMLiVE

GSK found UK’s drug pricing changes a tough sell

Firm's chief executive met with the government to question the last PPRS update

- PMLiVE

Kythera bags FDA approval for double chin therapy

Comes as cosmetics industry sees major growth

- PMLiVE

Harvoni sales rocket in first quarter

Gilead’s new hepatitis C pill generates stellar revenue

- PMLiVE

Good Relations appoints Louise Veale to consumer health team

She joins as an associate director and will report to Kelly Blaney

- PMLiVE

FDA panel backs Amgen’s T-Vec for melanoma

Approved by a panel of 22 to one despite questions on its impact on survival

Sanofi reception

Poor Lantus sales sees Sanofi’s diabetes unit fall

French firm hit by insulin pricing pressures and soon faces biosimilar threat

- PMLiVE

Perrigo rejects Mylan again as Teva bites back

There is much debate over the value of the company’s shares

- PMLiVE

RSA boosts its German speaking divisions

Appoints Andreas Reimer and Ji Kwon

Portcullis Public Affairs teams up to launch The Portcullis Group

Joins with New Media Business Group to form agency

- PMLiVE

More money for the NHS – but is this the answer?

Politicians opening their pre-election cheque books can’t put the UK’s health service where it needs to be – but pharma could have a major role to play

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links